Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.3K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K
Mutations01:39

Mutations

85.4K
Overview
85.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An oncostatin M receptor and chloride intracellular channel 1 crosstalk drives key oncogenic pathways in glioblastoma.

Signal transduction and targeted therapy·2026
Same author

Global mitochondrial connectivity map reveals the landscape of yeast functional assemblies and conserved protein communities.

Nature communications·2026
Same author

Assessment of HIF2α mutational pathogenicity using microscale thermophoresis.

Biology methods & protocols·2026
Same author

A Two-Step Strategy for Aroma Restoration of Strawberry Concentrate Based on ZIF-67@PDMS Composite Membrane.

Foods (Basel, Switzerland)·2026
Same author

Early wide systolic pressure excursion is associated with clinical outcomes in acute branch atheromatous disease.

Frontiers in neurology·2026
Same author

An OSMR-CLIC1 cross talk drives key oncogenic pathways in glioblastoma.

bioRxiv : the preprint server for biology·2025
Same journal

UPF3A and UPF3B shape the transcriptome cooperatively yet oppose cell function.

Journal of molecular biology·2026
Same journal

Antibody-secreting cells integrate efficient NMD with non‑canonical UPR signaling to maintain proteostasis and support massive immunoglobulin synthesis.

Journal of molecular biology·2026
Same journal

Small molecule stabilization of diverse amyloidogenic immunoglobulin light chains revealed by hydrogen-deuterium exchange mass spectrometry.

Journal of molecular biology·2026
Same journal

UPF1 at Work: Structural and Mechanistic Insights Into a Master Regulator of Nonsense-Mediated mRNA Decay.

Journal of molecular biology·2026
Same journal

Structural basis for the pro-amyloidogenic action and ligand binding of a novel W72R variant of human apolipoprotein A-I.

Journal of molecular biology·2026
Same journal

Cryo-EM Structure of the C. Elegans Septin Tetramer Reveals a Revised Architecture and Conserved Positional Orthology.

Journal of molecular biology·2026
See all related articles

Related Experiment Video

Updated: Oct 10, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K

D154Q Mutation does not Alter KRAS Dimerization.

Ingrid Grozavu1, Sarah Stuart2, Anna Lyakisheva1

  • 1Donnelly Centre, University of Toronto, Toronto, ON, Canada; Department of Biochemistry, University of Toronto, Toronto, ON, Canada.

Journal of Molecular Biology
|December 13, 2021
PubMed
Summary
This summary is machine-generated.

Caution is advised when using the KRAS D154Q mutant to study KRAS dimerization in cancer. This variant forms dimers with wild-type KRAS, indicating it is not dimer-deficient as previously thought.

Keywords:
Cancer therapeuticsKRASMaMTHOncogenic signallingSIMPLco-immunoprecipitationdimerization

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.8K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Related Experiment Videos

Last Updated: Oct 10, 2025

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.8K
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

8.8K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • KRAS is a frequently mutated oncogene in human cancers.
  • KRAS remains largely undruggable due to incomplete biological understanding.
  • KRAS dimerization is crucial for its signaling function in oncogenesis.

Purpose of the Study:

  • To investigate the dimerization properties of the KRAS D154Q mutant.
  • To determine if the KRAS D154Q mutant can be used to study the role of dimerization in KRAS oncogenicity.
  • To assess the impact of the D154Q mutation on oncogenic KRAS dimerization.

Main Methods:

  • Utilized three distinct protein-protein interaction assays.
  • Analyzed homo- and heterodimerization of KRAS D154Q with wild-type KRAS (KRAS WT).
  • Evaluated the effect of the D154Q mutation on oncogenic KRAS dimerization.

Main Results:

  • The KRAS D154Q mutant demonstrated homo- and heterodimerization with KRAS WT.
  • Oncogenic KRAS dimerization was not impaired by the presence of a secondary D154Q mutation.
  • The D154Q variant is not dimer-deficient as previously suggested.

Conclusions:

  • The KRAS D154Q mutant forms dimers and is not suitable for studying dimer-deficiency.
  • Caution is recommended when using the D154Q variant to investigate the role of dimerization in KRAS oncogenic behavior.
  • Further research is needed to understand KRAS biology and develop effective KRAS-targeted therapies.